Oligodendroglioma

Dr. Paleologos is currently Director of Neuro Oncology and Director of Neurology for Advocate Medical Group, the largest physician group in Illinois, with Advocate Healthcare including 12 Hospitals in Illinois. Advocate Healthcare is also part of Advocate Aurora Health. She is also Professor (Adjunct) of Neurological Sciences, Rush University Medical School in Chicago, IL. She has published over 60 journal articles and book chapters in the fields of Neuro-Oncology and Neurology. She has been named as a Best Doctor’s in America (2005-2019) and as a Top Doctor in Chicago in Neurology for several years. She was one of two neuro oncologists named as Chicago Magazine's best neuro oncologists in Chicago and received a Career Acheivement Award from the Chicago Neurological Society for "exceptional expertise, knowledge, dedication and recognition in the field of Neuro-Oncology" in 2013. She has been Chair of the Section of Neurology for the American Academy of Neurology, and is Chairman of the Neuro Oncology Exam Committee for the United Council of Neurological Subspecialities. Herbert B. Newton, M.D., FAAN, is currently the Medical Director for the Neuro-Oncology Program and Brain Tumor Institute at the University Hospitals Cleveland Medical Center and Seidman Cancer Center, in Cleveland, Ohio, where he is also a Professor of Neurology and Solid Tumor Oncology, and holds the William Burton Risman Neurological Institute Chair in Memory and Cognition. Prior to that he was the Director of the Neuro-Oncology Center and Medical Neuro-Oncology Program at the Advent Health Cancer Institute and Advent Health Orlando Campus in Orlando, Florida. He is also retired as a Professor of Neurology and Neurosurgery, Dardinger Neuro-Oncology Center, Esther Dardinger Endowed Chair in Neuro-Oncology and Division of Neuro-Oncology at the Ohio State University Medical Center and James Cancer Hospital, in Columbus, Ohio. He is a Diplomate of the American Board of Psychiatry and Neurology, a Fellow of the American Academy of Neurology and Royal Society of Medicine, and a member of numerous national and international societies.

• SECTION I. CLINICAL PRESENTATION AND QUALITY OF LIFE1. Clinical Presentation in Adults - Brain2. Clinical Presentation of Spinal Oligodendrogliomas3. Oligodendrogliomas – Atypical Clinical Presentations4. Clinical Presentation of Pediatric Oligodendrogliomas5. Seizures & Oligo’s6. Living with OligodendrogliomaSECTION II. PATHOLOGY AND MOLECULAR BIOLOGY7. Origin and Development of Oligodendroglioma8. Pathology and Molecular Biology Oligo’s9. The role of biomarkers in the diagnosis and treatment of oligodendrogliomas10. Prospects of translational proteomics and protein microarrays in oligodendroglioma11. Pathology of Pediatric Oligodendroglioma SECTION III. NEURO-IMAGING 12. CT Imaging of Oligodendroglioma13. Routine and Advanced Magnetic Resonance Imaging of Oligodendrogliomas14. Advanced [11C] Methionine and [18F] FDG Positron Emission Tomography for Diagnosis, Treatment, and Follow Up of Oligodendrogliomas15. Neuroimaging of Pediatric OligodendrogliomasSECTION IV. SURGICAL THERAPY16. Oligodendrogliomas: Basic Techniques in Surgery17. Oligodendrogliomas: Advanced Techniques in Surgery18. Surgical management of 1p/19q co-deleted oligodendrogliomas WHO grade II and III19. Surgical Results in Anaplastic Oligodendroglioma (AO) and Anaplastic Oligoastrocytoma (AOA)20. Surgical Management of Pediatric OligodendrogliomaSECTION V. RADIATION THERAPY 21. Basic Principles of Brain Tumor Radiotherapy22. Standard External Beam Radiation Therapy for Oligodendroglioma23. Stereotactic Radiosurgery in the management of Oligodendroglioma24. Proton Beam Therapy for Oligodendroglioma 25. Interstitial Brachytherapy treatment for Oligodendrogliomas26. The Role of Radiation in Pediatric OligodendrogliomasSECTION VI. CHEMOTHERAPY AND IMMUNOTHERAPY27. Basic Principles of Brain Tumor Chemotherapy28. The use of PCV Chemotherapy in Oligodendrogliomas29. Temozolomide Chemotherapy for Oligodendroglial Tumors30. Miscellaneous Chemotherapy Approaches to Oligodendroglial Tumors31. Molecular Therapy for Oligodendrogliomas32. Bevacizumab for Recurrent Anaplastic Oligodendroglial Tumors33. Pediatric Oligodendroglioma34. Immune Checkpoint Blockade in Glioma